Related Experiment Video

Updated: Sep 15, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Asis Shrestha1, Sharmilan Thanendrarajan1, Aishee Bag2

  • 1University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.

Blood Advances
|July 17, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K

Related Experiment Videos

Last Updated: Sep 15, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

Articles linked to this work by shared authors, journal, and citation graph.

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis.

Cancer·2026

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.

The New England journal of medicine·2026

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

Haematologica·2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Blood advances·2026

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study.

Blood·2026

Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis.

Cancers·2026

Allogeneic stem cell transplantation in aggressive Adult T cell leukemia/lymphoma: a prospective multicenter study.

Blood advances·2026

Interpreting pulmonary function tests in allogeneic hematopoietic cell transplant recipients.

Blood advances·2026

Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.

Blood advances·2026

The total serum N-glycome landscape of hematological malignancies.

Blood advances·2026

Chromatin-informed cell-free DNA approach for detection of clinically measurable disease in multiple myeloma.

Blood advances·2026

Impact of Metformin on the Incidence of Thrombosis in Older Adults with Polycythemia Vera or Essential Thrombocythemia and Diabetes.

Blood advances·2026

Catecholamine-Secreting Retroperitoneal Paraganglioma: A Case Report and Literature Review.

Case reports in urology·2026

Incidence and reasons for cancellation on the day of elective surgery: a systematic review and meta-analysis.

Anaesthesia·2026

CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML.

Genome medicine·2026

Single-cell transcriptomics reveals transcriptional reprogramming and microenvironmental remodeling in ectopic ACTH/CRH-secreting pheochromocytomas.

Journal of translational medicine·2026

CUE domain-containing 2 promotes diffuse large B-cell lymphoma progression via PP2A-B55β degradation and shapes macrophage-mediated immune responses.

Molecular biomedicine·2026

FDXR upregulation by p63/p73 is a prognostic and therapeutic marker of adult T-cell leukemia/lymphoma.

EMBO molecular medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us